Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.67 USD
+0.20 (13.61%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.66 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Gain Therapeutics, Inc. has a market cap of $44.20M, which represents its share price of $1.47 multiplied by its outstanding shares number of 30.07M. As a small-cap company, GANX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GANX 1.67 +0.20(13.61%)
Will GANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 9th
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GANX
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference | GANX Stock News
Gain Therapeutics (GANX) Announces Public Offering of Shares | GANX Stock News
Newbridge Securities Leads Offering for GANX | GANX Stock News
Gain Therapeutics announces pricing of $7M public offering
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering | GANX Stock News